Bli medlem
Bli medlem

Du är här


World MS Day: Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS

Novartis International AG / World MS Day: Novartis launches 7-Day Challenge to
'Live Like You' enablingpeople with MS to better understand their lives with
MS . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer
is solely responsible for the content of this announcement.
* 7-Day Challenge integrates wearable technology and social media to track
daily activities of people with MS, allowing valuable personal insights to
enable change
* Novartis is collaborating with Tictrac, a personal analytics company, to
empower people with MS via a personal tracking system, to learn more about
their lives
* There is a high interest amongst the MS community to learn about their
lifestyles in order to make adjustments that can help to improve their
daily lives with MS

The digital press release with multimedia content can be accessed here:

Basel, May 28, 2014
- In support of World MS Day, Novartis announced today the launch of the 7-Day
Challenge to Live Like You for people with MS. The 7-Day Challenge to Live
Like You, one of the first integrations of emerging technological trends by a
pharmaceutical company, is simple: using wearable technology or accessing
personal online systems that people use on a daily basis, including
calendars, social media channels and fitness trackers, people with MS are
invited to track their activities for seven days and gain valuable insights
into what works best for their lifestyle. The 7-Day Challenge to Live Like
You, which can be accessed via, addresses the
growing desire amongst the MS community to gather personalized information
that will allow them to make decisions on how they can manage their lives
with MS.

World MS Day was created by the Multiple Sclerosis International Foundation
(MSIF) in 2009 to raise global awareness of MS and its impact on
approximately 2.3 million people with MS[1] around the world. This year's
World MS Day campaign focuses on 'access'. Importantly, the topic of access
spans beyond access to treatment in MS. Increasingly, there is a need for
access to relevant and personalized online information that allows people to
utilize available tools in order to make adjustments that can help them to
manage their MS in a way that best suits their lifestyle.

"Novartis is a proud supporter of World MS Day, and we recognize the value of
providing access to personalized information for the MS community," said
David Epstein, Division Head, Novartis Pharmaceuticals. "As part of our
commitment to providing innovative solutions that go beyond treatments, we
are delighted to announce the launch of the 7-Day Challenge to Live Like You,
which will empower the MS community to gain valuable insights about
themselves and their MS."

The 7-Day Challenge to Live Like You is a collaboration between Novartis and
Tictrac, an innovative technology company with expertise in tracking user
data and turning the data into unique perceptions (e.g. 'you're more active
after a good night's sleep') that can help people with MS better understand
their lifestyle in order to make small changes based on their new insights.
Alongside the 7-Day Challenge to Live Like You, Novartis also recently
launched Living Like You (, an online resource
community that features personal content for the MS community.

For people with MS, personalized information and tracking is essential because
it can help with symptom management and take the guesswork out of what is and
isn't working - and allow small changes that could help in achieving
meaningful results. The tracking does not need to stop after the seven days
are up; the 7-Day Challenge to Live Like You online tracking program will
still be available to the MS community, to empower people with MS to continue
to gain valuable insights about themselves and how to better manage their
life with this debilitating disease.

About Living Like You

The Novartis-supported Living Like You ( is an online
resource community that features magazine-style content detailing the journey
through the realities of life with MS by offering insights from people who
live with the disease. Providing access to relevant information online is
important as people with MS are up to three times more likely to be online
compared to people with other diseases[2]; in fact, MS is mentioned online
every 13 seconds.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic disorder of the central nervous system
(CNS) that disrupts the normal functioning of the brain, optic nerve and
spinal cord[3]. The evolution of MS results in an increasing loss of both
physical (e.g. difficulty with walking) and cognitive (e.g. problems with
mental tasks or memory) function[4]. This has a substantial negative impact
on the approximately 2.3 million people worldwide affected by MS[1], a
disease that begins in early adulthood, most often between the ages of 20 and

The loss of physical and cognitive function is driven by two main types of
damage that both contribute to widespread loss of neurons (nerve cells in the
brain and spinal cord that transmit impulses): discrete inflammatory lesions,
focal damage, in the brain that can clinically manifest as relapses; and
ongoing, more diffuse damage that starts early in the disease and causes the
progressive loss of brain tissue, including neurons, and over time is
associated with both physical and cognitive problems[6]-[8].

About Novartis in Multiple Sclerosis

Novartis is committed to the research and development of new treatment options
to offer the right treatment to the right patient at the right time, to meet
patients' needs at every stage of disease with innovative and targeted drugs.

In addition to its ongoing development program for Gilenya in primary
progressive MS (PPMS), pediatric MS and chronic inflammatory demyelinating
polyneuropathy (CIPD), the Novartis MS portfolio includes Extavia®(interferon
beta-1b for subcutaneous injection). Investigational compounds include BAF312
(siponimod), which is currently in Phase III clinical development and being
developed as the first oral therapy for secondary progressive MS (SPMS), and
VAY736, an anti-B-cell compound for MS that is currently being investigated
in proof of concept studies. Novartis is also exploring the IL-17 pathway in


The foregoing release contains forward-looking statements that can be
identified by words such as "launches," "can," "growing," "will,"
"commitment," "launch," "committed," "ongoing," "investigational,"
"exploring," or similar terms, or by express or implied discussions regarding
potential new indications or labeling for Gilenya, potential future marketing
submissions or approvals for the investigational compounds in the Novartis MS
portfolio, or regarding potential future revenues from any of the products
and investigational compounds in the Novartis MS portfolio. You should not
place undue reliance on these statements. Such forward-looking statements are
based on the current beliefs and expectations of management regarding future
events, and are subject to significant known and unknown risks and
uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that Gilenya will be submitted or approved for any
additional indications or labeling in any market, or at any particular time.
Neither can there be any guarantee that any of the investigational compounds
in the Novartis MS portfolio will be submitted or approved for sale in any
market, or at any particular time. Nor can there be any guarantee that any
of the products and investigational compounds in the Novartis MS portfolio
will be commercially successful in the future. In particular, management's
expectations regarding these products could be affected by, among other
things, the uncertainties inherent in research and development, including
unexpected clinical trial results and additional analysis of existing
clinical data; unexpected regulatory actions or delays or government
regulation generally; the company's ability to obtain or maintain proprietary
intellectual property protection; general economic and industry conditions;
global trends toward health care cost containment, including ongoing pricing
pressures; unexpected manufacturing issues, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care, cost-saving generic pharmaceuticals, preventive
vaccines, over-the-counter and animal health products. Novartis is the only
global company with leading positions in these areas. In 2013, the Group
achieved net sales of USD 57.9 billion, while R&D throughout the Group
amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 135,000 full-time-equivalent associates and sell products in
more than 150 countries around the world. For more information, please


Accessed May 2014.

[2] Data on file. Novartis Pharmaceuticals. 'Multiple Sclerosis on the Social
Web' social web audit.
[3] Accessed May 2014.

[4] Accessed
May 2014.

[5] Accessed May 2014.

[6] Filippi M et al. Association between pathological and MRI findings in
multiple sclerosis. Lancet Neurol. 2012 Apr;11(4):349-60.
[7] Kutzelnigg A et al. Cortical demyelination and diffuse white matter injury
in multiple sclerosis. Brain. 2005 Nov;128(Pt 11):2705-12.
[8] Sormani MP, Arnold DL&De Stefano N. Treatment effect on brain atrophy
correlates with treatment effect on disability in multiple sclerosis. Ann
Neurol. 2014 Jan;75(1):43-9.

# # #

Novartis Media Relations

|Central media line : |
|+41 61 324 2200 ...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.